Navigation Links
Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
Date:6/1/2010

EMERYVILLE, Calif., June 1 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

"Based on insights gained from our ongoing carfilzomib development program and ONX 0912's favorable preclinical profile – anti-tumor activity, safety and biodistribution – we believe ONX 0912 may have the potential to expand the use of proteasome inhibitors in the treatment of cancer," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development at Onyx Pharmaceuticals.  "As an orally-dosed agent, ONX 0912 is designed to provide prolonged proteasome inhibition and easy combinability with other orally available therapies."  

Trial Design

This multicenter, open-label, dose-escalation study is evaluating the safety and tolerability of ONX 0912 in up to 50 patients with advanced refractory or recurrent solid tumor malignancies for which standard curative measures do not exist or are no longer effective.  The trial will determine the maximum tolerated dose (MTD), dose limiting toxicities, and pharmacokinetics/pharmacodynamics of ONX 0912 when administered orally on days 1 through 5 of a 14-day cycle.  Cohorts of 3 to 6 patients will receive ONX 0912 at escalating doses, starting at 30 mg, until MTD is determined.  Treatment will be repeated in 14-day cycles. The trial will be conducted in the United States.

About Onyx's Proteasome Inhibitor Development Program


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oramed Pharmaceuticals Announces Publication of Research Article on its Oral Insulin Capsule ORMD-0801 in Diabetes, Obesity and Metabolism
2. Co-Founder Gavin MacBeath, Ph.D. Joins Merrimack Pharmaceuticals as a Senior Director and the Head of Translational Research
3. Biostar Pharmaceuticals, Inc. Begins Assembly of New Production Line
4. Sinovac to Present at 2010 UBS Global Specialty Pharmaceuticals Conference
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Amylin Pharmaceuticals to Present at the 2010 Citi Investment Research Global Healthcare Conference
7. Oramed Pharmaceuticals Announces That Dr. Michael Berelowitz, Senior Vice President at Pfizer, Joins its Board of Directors
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
10. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
11. Renhuang Pharmaceuticals Exhibits All-Natural Products at the 63rd PHARMACHINA Fair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... April 30, 2015   Tamir Biotechnology , a ... update on its Ebola antiviral therapy program. ... TMR004, is currently being evaluated and considered by a ... against Ebola. During the first quarter of 2015, the ... To Accelerate The Evaluation of Potential Treatments and Vaccines ...
(Date:4/30/2015)... 2015 Nitto Avecia, a leading ... increased capacity and production capability to serve biotechnology ... and service fulfillment continues to drive Nitto Avecia ... throughput capacities. , In Fall 2014, ... process equipment at its Milford, MA facility, which ...
(Date:4/30/2015)... Cambridge, MA & Budapest, Hungary (PRWEB) April 30, ... the only web-based electronic lab notebook with integrated ... leader in providing chemistry software solutions and consulting ... that led to the development of Labguru’s newest ... a set of deep domain features for biologists, ...
(Date:4/30/2015)... , April 30, 2015  Asterias Biotherapeutics, Inc. ... emerging field of regenerative medicine, today announced that it ... Thursday, May 7, 2015 after the close of the ... call and webcast on Thursday, May 7, 2015 at ... the results and recent corporate developments. For ...
Breaking Biology Technology:Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4Biotechnology Manufacturer Nitto Avecia Expands Capacity to Meet Client Demand 2Labguru Integrates ChemAxon's Marvin JS, to Enhance Functionality for Chemists 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3
... (Nasdaq: BMRN ) today announced that Jean-Jacques,Bienaime, Chief ... the 3rd Annual Citi Biotech Day in New York ... Interested parties may access a live audio webcast ... BioMarin website, http://www.BMRN.com .,A replay of the call ...
... ANGELES, Sept. 2 Signalife, Inc. (Amex:,SGN) announced ... tomorrow, at,the opening of the market, regarding the ... About Signalife, Signalife, Inc. is a life ... of disease through continuous biomedical signal,monitoring. Signalife uses ...
... Genome,Sciences, Inc. (Nasdaq: HGSI ) announced today ... Annual Healthcare Conference will be webcast,and may be ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ), A member of Human ... overview on Thursday, September 4, 2008 at 8:35 ...
Cached Biology Technology:BioMarin to Present at the Citi Biotech Day 2Signalife to Issue Breaking News Regarding Vianale & Vianale Tomorrow 2
(Date:3/24/2015)... , March 24, 2015   Crossmatch ™, ... today announced that its U.are.U ® 4500 ... Goorin Bros . to achieve PCI compliance ... secures access to the POS terminal, protecting the ... of data breaches. With one-third ...
(Date:3/23/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, announces its biometric payment technology, the Wocket® smart ... starting March 30 th . The ... New York markets. Gino ... our new ad campaign following the recent initial shipment of ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... $20,000 grant from Orvis Company, Inc. that will help fund ... "Path of the Pronghorn." For more than a ... of pronghorn along the path between wintering grounds in the ... National Park (GTNP). This led to collaboration with GTNP and ...
... (TUM) under Prof. Peter Schieberle and at the University of ... and oils: Lard, butterfat, rapeseed oil and olive oil. Over ... grams of low-fat yoghurt enriched with one of the four ... their normal diet. "Olive oil had the biggest satiety ...
... and the Carlos III University of Madrid have patented a ... a specific street carries each day, by measuring solely the ... world, is an alternative, or a complement, to other methods ... or magnetic discharge levels. This method, designed by the ...
Cached Biology News:More good news for pronghorn 2Olive oil makes you feel full 2A new method for measuring the flow of traffic a street has to bear by measuring atmospheric noise 2
GOAT ANTI HUMAN PSA (ISOFORM 1)...
p-Raf-1 (Ser 338/Tyr 341)-R...
... Lauryl Ether 30% concentration ... Preservative. Surfactant. Clear Solution. ... is 1 mL of ... added to 400 mL ...
Mitotic Kinesin-Like Protein 1 (MKLP-1, KNSL5)...
Biology Products: